Get the Stockscreener App
7.37
3.08%
0.22
After Hours:
7.42
0.05
+0.68%
Regenxbio Inc stock is traded at $7.37, with a volume of 675.63K.
It is up +3.08% in the last 24 hours and down -12.99% over the past month.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
See More
Previous Close:
$7.15
Open:
$7.27
24h Volume:
675.63K
Relative Volume:
0.64
Market Cap:
$365.15M
Revenue:
$89.04M
Net Income/Loss:
$-241.08M
P/E Ratio:
-1.4011
EPS:
-5.26
Net Cash Flow:
$-194.72M
1W Performance:
-1.86%
1M Performance:
-12.99%
6M Performance:
-44.50%
1Y Performance:
-47.95%
1-Day Range:
$7.1825
$7.435
1-Week Range:
$6.56
$7.70
52-Week Range:
$6.56
$28.80
Regenxbio Inc Stock (RGNX) Company Profile
Name
Regenxbio Inc
Sector
Industry
Phone
240-552-8181
Address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
7.37 | 365.15M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-15-24 | Resumed | Morgan Stanley | Overweight |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jun-07-24 | Initiated | Goldman | Buy |
| Mar-11-24 | Initiated | H.C. Wainwright | Buy |
| Mar-08-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-21-24 | Resumed | Raymond James | Outperform |
| Nov-01-23 | Initiated | Stifel | Buy |
| Jun-02-23 | Initiated | Robert W. Baird | Outperform |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-15-21 | Initiated | Wedbush | Neutral |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jan-06-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-20-19 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Jun-18-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-14-19 | Resumed | Raymond James | Outperform |
| Jun-05-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-25-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-05-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-17-18 | Reiterated | Chardan Capital Markets | Buy |
| Nov-08-18 | Reiterated | BofA/Merrill | Neutral |
| Aug-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-23-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-10-18 | Reiterated | Chardan Capital Markets | Buy |
| May-09-18 | Reiterated | Barclays | Overweight |
| Apr-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-13-18 | Initiated | Mizuho | Neutral |
| Nov-09-17 | Resumed | Morgan Stanley | Overweight |
View All
Regenxbio Inc Stock (RGNX) Latest News
Assenagon Asset Management S.A. Has $6.62 Million Position in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
Regenxbio and Nippon Shinyaku forge $810m gene therapy deal - MSN
(RGNX) Technical Data - Stock Traders Daily
Nippon Shinyaku, REGENXBIO partner for MPS treatments in U.S. and Asia -January 17, 2025 at 08:01 am EST - Marketscreener.com
Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121 - Seeking Alpha
Asia Deal Watch: Regenxbio Licenses Two MPS Gene Therapies To Nippon Shinyaku - Scrip
REGENXBIO: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026 (NASDAQ:RGNX) - Seeking Alpha
REGENXBIO partners with Nippon Shinyaku for MPS therapies - MSN
Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again (NASDAQ:RGNX) - Seeking Alpha
Regenxbio, Nippon Shinyaku Partner for MPS II, MPS I Gene Therapies - Contract Pharma
Regenxbio maintained at Buy rating by H.C. Wainwright post partnership announcement - Investing.com India
Regenxbio maintained at Buy by H.C. Wainwright post partnership announcement - Investing.com Australia
Regenxbio Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga
REGENXBIO (NASDAQ:RGNX) Receives Buy Rating from HC Wainwright - MarketBeat
Regenxbio inks MPS drugs collab with Nippon Shinyaku - The Pharma Letter
AbbVie, REGENXBIO advance gene therapy for eye diseases By Investing.com - Investing.com Australia
Rockville’s RegenxBio Enters $810 Million Partnership with Japanese Firm to Launch New Treatments - The MoCoShow
Rockville’s RegenxBio strikes potential $810M deal with Japan’s Nippon Shinyaku - Washington Business Journal
Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku - BioPharma Dive
Regenxbio stock hits 52-week low at $7.13 amid market challenges - Investing.com Australia
RegenXBio Partners with Nippon Shinyaku on Gene Therapies - TipRanks
Regenxbio stock surges on strategic partnership deal with Nippon Shinyaku By Investing.com - Investing.com Australia
Regenxbio stock surges on strategic partnership deal with Nippon Shinyaku - Investing.com
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases - Longview News-Journal
Barclays PLC Raises Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
AbbVie, REGENXBIO advance gene therapy for eye diseases - Investing.com India
AbbVie (ABBV) and REGENXBIO (RGNX) Announce Updates on the ABBV-RGX-314 Clinical Program - StreetInsider.com
AbbVie and REGENXBIO Advance Revolutionary One-Time Gene Therapy for Vision Loss Treatment - StockTitan
Regenxbio stock hits 52-week low at $7.13 amid market challenges By Investing.com - Investing.com South Africa
Regenxbio stock jumps 13% on positive data for DMD drug - MSN
BlackRock, Inc. Reduces Stake in Regenxbio Inc: A Strategic Port - GuruFocus.com
Jane Street Group LLC Sells 35,994 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Regenxbio price target lowered to $22 from $25 at BofA - Yahoo Finance
JPMorgan Chase & Co. Decreases Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
JPMorgan Chase & Co. Cuts Stake in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Principal Financial Group Inc. Sells 11,064 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI - GlobeNewswire Inc.
Geode Capital Management LLC Raises Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
RGNX stock touches 52-week low at $7.15 amid market challenges - Investing.com Australia
RGNX stock touches 52-week low at $7.15 amid market challenges By Investing.com - Investing.com South Africa
Barclays PLC Purchases 67,948 Shares of REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Barclays PLC Has $1.22 Million Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - MarketBeat
REGENXBIO Inc. (NASDAQ:RGNX) Short Interest Up 18.4% in December - MarketBeat
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 26% Dive - Simply Wall St
(RGNX) Investment Analysis - Stock Traders Daily
Fmr LLC Boosts Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Regenxbio Inc Stock (RGNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):